Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of pyrro-quinoline quinine in treating and preventing atherosclerosis

A technology for atherosclerosis and roloquinoline quinone, which is applied in the field of vascular diseases and can solve the problems of research on the prevention and/or treatment of atherosclerosis without PQQ active substances

Active Publication Date: 2012-04-18
ZHUCHENG HAOTIAN PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, prior to the present invention, no research has been done on the use of PQQ active substances for the prevention and / or treatment of atherosclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pyrro-quinoline quinine in treating and preventing atherosclerosis
  • Application of pyrro-quinoline quinine in treating and preventing atherosclerosis
  • Application of pyrro-quinoline quinine in treating and preventing atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Example 1: Inhibitory Effect of PQQ on Low Density Lipoprotein (LDL) Oxidation

[0090] experimental method:

[0091]1. Preparation of LDL: Take fresh plasma from healthy adults (obtained from volunteer donations), obtain an EDTA-containing LDL solution by density gradient sequence ultracentrifugation (reference 5: Lindgren, Jensen et al. 1969), and dissolve the solution in PBS The solution (pH7.5) was dialyzed and desalted (4°C, 4 hours), the resulting LDL solution was diluted to 200 mg / L, and the protein content was determined according to the Lowry method;

[0092] 2. LDL oxidation experiment: CuSO with a concentration of 5 μM 4 The LDL solution obtained in step 1 was diluted to a final concentration of 15 μg / ml to induce LDL oxidation (Reference 1: Esterbauer, Striegl et al., 1989). 25 μg / ml and 50 μg / ml of PQQ were added to the reaction system, and the LDL oxidation curve was drawn by measuring the absorbance of conjugated dienoic acid at 234 nm at different ti...

Embodiment 2

[0097] Example 2: The protective effect of PQQ on endothelial cells

[0098] experimental method:

[0099] 1. Cells and culture conditions: Under sterile conditions, the umbilical cords of newborn fetuses (obtained from Shanghai Obstetrics and Gynecology Hospital) were taken immediately after delivery from healthy puerperas, digested with 0.1% collagenase, and the obtained human umbilical vein endothelial cells were prepared according to Conventional adherent cell culture method for subculture (reference 4: Jaffe, Nachman et al. 1973);

[0100] The composition of the cell culture medium is: DMEM medium 1g, NaHCO 3 0.36g, 1000u each of penicillin and streptomycin, 10mL of fetal bovine serum, add water to 100mL. 37°C, 5% CO 2 Cultivate in an incubator, change the medium after 24 hours, passage and digest when the cell density is about 80%, and take the 2-3 generation cells for experiments;

[0101] 2. PQQ pretreatment: culture umbilical vein endothelial cells in a 96-well...

Embodiment 3

[0109] Example 3: The effect of PQQ on reducing the content of cholesterol in the arteries of atherosclerosis rat model

[0110] experimental method:

[0111] 1. Take several SD male rats aged 6 weeks and weighing about 220g, and raise them under standard conditions;

[0112] 2. The rats were randomly divided into 4 groups, 6 in each group. The groupings are as follows:

[0113] Group 1: Control group: ordinary SD rats fed with feed;

[0114] Group 2: High cholesterol diet group (HCD);

[0115] Group 3: High cholesterol plus low-dose PQQ group, PQQ was given with meals.

[0116] Group 4: High cholesterol plus high-dose PQQ group, PQQ was given with meals.

[0117] Wherein, the composition of high cholesterol diet in group 2-group 4 is: 2% cholesterol, 3% lard, 0.5% bile acid and 0.2% propylthiouracil, add in common feed;

[0118] The oral dose of PQQ in the low-dose PQQ group was: 0.5 mg / kg / d;

[0119] The oral dose of PQQ in the high-dose PQQ group was: 1.0 mg / kg / d. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of pyrro-quinoline quinine in treating and preventing atherosclerosis and also provides a health-care product composition or a medical composition containing pyrro-quinoline quinine. The pyrro-quinoline quinine can suppress the oxidization of low-density lipoprotein, protect endothelial cells and reduce the content of lipid in endothelium and the area of atheromatous plaques, thus the pyrro-quinoline quinine has good application prospect in preventing and / or treating the forming and the development of the atherosclerosis.

Description

technical field [0001] The present invention relates to the field of vascular diseases. More specifically, the present invention relates to the application of pyrroloquinoline quinone in the treatment and / or prevention of atherosclerosis. Background technique [0002] Atherosclerosis is a lesion that invades arteries and blood vessels. It causes coronary heart disease, cerebrovascular disease and peripheral vascular disease, which seriously endangers human health. Its morbidity and mortality rank among the forefront of various diseases. Epidemiological surveys show that the incidence of cardiovascular disease in some developed countries is close to 10%, and the annual death toll in the world accounts for 10% of the total population death toll. There are more than 7 million patients with cardiovascular and cerebrovascular diseases in my country, and there are even more patients with atherosclerotic lesions, and their morbidity and mortality are increasing year by year, while...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4745A61P9/10A61P7/02A61P35/00
Inventor 顾建新恽小婧周蕾
Owner ZHUCHENG HAOTIAN PHARMA